This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Venkatasubbarao, K. Articles by Freeman, J. W. Search for Related Content PubMed PubMed Citation Articles by Venkatasubbarao, K. Articles by Freeman, J. W.

Reversion of Transcriptional Repression of Sp1 by 5 aza-2' Deoxycytidine Restores TGF-ß Type II Receptor Expression in the Pancreatic Cancer Cell Line MIA PaCa-2¹

Department of Surgery, University of Texas Health Science Center, San Antonio, Texas 78229-3900

The pancreatic cancer cell line, MIA PaCa-2 is not responsive to transforming growth factor ß (TGF-ß) because of a lack of expression of the TGF-ß type II receptor (RII). We show that the lack of RII expression is caused by a deficit of the transcription factor Sp1. Nuclear run-off assays and Western immunoblot showed low levels of transcription and protein levels of Sp1, respectively. Treatment of MIA PaCa-2 cells with the DNA methyl transferase inhibitor, 5-aza-2'-deoxycytidine, resulted in an increase in the rate of Sp1 transcription, in Sp1 protein expression, and in the binding of Sp1 to the RII promoter. Ectopic expression of Sp1 cDNA in MIA PaCa-2 cells led to an increase in RII promoter-chloramphenicol acetyltransferase activity and RII expression. Expression of Sp1 cDNA also caused a reduction in both growth and clonogenicity that was associated with restoration of responsiveness to TGF-ß. Conversely, cells that express RII (BxPC-3 and MIA PaCa-2 Sp1 transfectants) when treated with mithramycin, an inhibitor of Sp1 binding, showed a reduction in RII mRNA expression. The reduction of RII mRNA was attributed to a decrease in RII promoter-chloramphenicol acetyltransferase activity that was associated with a decrease in Sp1 binding to the RII promoter. These data indicate that transcriptional repression of the Sp1 gene in MIA PaCa-2 cells plays a role in the transcriptional inactivation of the RII gene and thus lack of responsiveness to TGF-ß.

This article has been cited by other articles:

				M. J. Truty, G. Lomberk, M. E. Fernandez-Zapico, and R. Urrutia Silencing of the Transforming Growth Factor-{beta} (TGF{beta}) Receptor II by Kruppel-like Factor 14 Underscores the Importance of a Negative Feedback Mechanism in TGF{beta} Signaling J. Biol. Chem., March 6, 2009; 284(10): 6291 - 6300. [Abstract] [Full Text] [PDF]

				A. Thangasamy, J. Rogge, and S. Ammanamanchi Regulation of RON Tyrosine Kinase-mediated Invasion of Breast Cancer Cells J. Biol. Chem., February 29, 2008; 283(9): 5335 - 5343. [Abstract] [Full Text] [PDF]

				W. Li, G. M. Venkataraman, and K. B. Ain Protein Synthesis Inhibitors, in Synergy with 5-Azacytidine, Restore Sodium/Iodide Symporter Gene Expression in Human Thyroid Adenoma Cell Line, KAK-1, Suggesting Trans-Active Transcriptional Repressor J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1080 - 1087. [Abstract] [Full Text] [PDF]

				M. Anbar, R. Bracha, Y. Nuchamowitz, Y. Li, A. Florentin, and D. Mirelman Involvement of a Short Interspersed Element in Epigenetic Transcriptional Silencing of the Amoebapore Gene in Entamoeba histolytica Eukaryot. Cell, November 1, 2005; 4(11): 1775 - 1784. [Abstract] [Full Text] [PDF]

				K. Venkatasubbarao, A. Choudary, and J. W. Freeman Farnesyl Transferase Inhibitor (R115777)-Induced Inhibition of STAT3(Tyr705) Phosphorylation in Human Pancreatic Cancer Cell Lines Require Extracellular Signal-Regulated Kinases Cancer Res., April 1, 2005; 65(7): 2861 - 2871. [Abstract] [Full Text] [PDF]

				R. L. Elliott and G. C. Blobe Role of Transforming Growth Factor Beta in Human Cancer J. Clin. Oncol., March 20, 2005; 23(9): 2078 - 2093. [Abstract] [Full Text] [PDF]

				S.S. Prime, M. Davies, M. Pring, and I.C. Paterson THE ROLE OF TGF-{beta} IN EPITHELIAL MALIGNANCY AND ITS RELEVANCE TO THE PATHOGENESIS OF ORAL CANCER (PART II) Critical Reviews in Oral Biology & Medicine, November 1, 2004; 15(6): 337 - 347. [Abstract] [Full Text] [PDF]

				S. Ammanamanchi, J. W. Freeman, and M. G. Brattain Acetylated Sp3 Is a Transcriptional Activator J. Biol. Chem., September 12, 2003; 278(37): 35775 - 35780. [Abstract] [Full Text] [PDF]

				Y. Bontemps, B. Vuillermoz, F. Antonicelli, C. Perreau, J.-L. Danan, F.-X. Maquart, and Y. Wegrowski Specific Protein-1 Is a Universal Regulator of UDP-glucose Dehydrogenase Expression: ITS POSITIVE INVOLVEMENT IN TRANSFORMING GROWTH FACTOR-{beta} SIGNALING AND INHIBITION IN HYPOXIA J. Biol. Chem., June 6, 2003; 278(24): 21566 - 21575. [Abstract] [Full Text] [PDF]

				S. Zhao, K. Venkatasubbarao, S. Li, and J. W. Freeman Requirement of a Specific Sp1 Site for Histone Deacetylase-mediated Repression of Transforming Growth Factor {beta} Type II Receptor Expression in Human Pancreatic Cancer Cells Cancer Res., May 15, 2003; 63(10): 2624 - 2630. [Abstract] [Full Text] [PDF]

				R. Bracha, Y. Nuchamowitz, and D. Mirelman Transcriptional Silencing of an Amoebapore Gene in Entamoeba histolytica: Molecular Analysis and Effect on Pathogenicity Eukaryot. Cell, April 1, 2003; 2(2): 295 - 305. [Abstract] [Full Text] [PDF]

				K. B. Glaser, J. Li, M. E. Aakre, D. W. Morgan, G. Sheppard, K. D. Stewart, J. Pollock, P. Lee, C. Z. O'Connor, S. N. Anderson, et al. Transforming Growth Factor {beta} Mimetics: Discovery of 7-[4-(4-Cyanophenyl)phenoxy]-Heptanohydroxamic Acid, a Biaryl Hydroxamate Inhibitor of Histone Deacetylase Mol. Cancer Ther., August 1, 2002; 1(10): 759 - 768. [Abstract] [Full Text] [PDF]